title: Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
abstract: OBJECTIVE
  We evaluated the efficacy and safety of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced metastatic transitional cell carcinoma of the urothelium.
  
  
  METHODS
  The subjects were 12 patients diagnosed with advanced metastatic transitional cell carcinoma of the urothelium. For mild hyperthermia, the patients' oral temperature was elevated to about 38 degrees C by heating for 20 min and retaining the heat for 20 min with a far-infrared heater. The antitumor effect was evaluated according to the RECIST, while adverse drug reactions were assessed based on the NCI-CTC.
  
  
  RESULTS
  The antitumor effect was rated as partial remission (PR) in 10 of the 12 patients and stable disease in 2 patients, with an efficacy rate of 83% (10/12). All 10 patients who had achieved PR received three courses of treatment. Of the 12 patients, 5 died during the observation period, with survival for 9-23 months (mean: 15.6 months). Adverse drug reactions included myelosuppression in all patients (Grade 3 in 4 patients, Grade 4 in 8), and gastrointestinal toxicity, such as nausea or vomiting, which was mild (Grade 0 in 2 patients, Grade 1 in 8, Grade 2 in 1, Grade 3 in 1).
  
  
  CONCLUSIONS
  The results of the present study suggest that M-VAC chemotherapy combined with mild hyperthermia, which potentiates the anticancer effect and reduces adverse drug reactions such as gastrointestinal symptoms, is a useful and safe method for the treatment of advanced transitional cell carcinoma of the urothelium.
authors.affiliation: Department of Urology, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan. yy1124@aichi-med-u.ac.jp
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Yamada
authors.forename: Youko
authors.initials: Y
authors.lastname: Itoh
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Aoki
authors.forename: Kogenta
authors.initials: K
authors.lastname: Nakamura
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Taki
authors.forename: Katsuya
authors.initials: K
authors.lastname: Naruse
authors.forename: Motoi
authors.initials: M
authors.lastname: Tobiume
authors.forename: Kenji
authors.initials: K
authors.lastname: Zennami
authors.forename: Remi
authors.initials: R
authors.lastname: Katsuda
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Kato
authors.forename: Masahito
authors.initials: M
authors.lastname: Watanabe
authors.forename: Genya
authors.initials: G
authors.lastname: Nishikawa
authors.forename: Miwako
authors.initials: M
authors.lastname: Minami
authors.forename: Mariko
authors.initials: M
authors.lastname: Nakahira
authors.forename: Sayaka
authors.initials: S
authors.lastname: Ukai
authors.forename: Masaki
authors.initials: M
authors.lastname: Sawada
authors.forename: Akiko
authors.initials: A
authors.lastname: Kitamura
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Honda
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000628:therapy; D012074:Remission Induction; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000188:drug therapy / Q000628:therapy*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate